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SuplatastTacrolimus Combination
Therapy for Refractory Facial
Erythema in Adult Patients with Atopic
Dermatitis―A Meta-Analysis Study―
Yoshiki Miyachi1, Ichiro Katayama2 and Masutaka Furue3
ABSTRACT
Background: Combination of suplatast tosilate with tacrolimus ointment was reported to reduce the dose of
tacrolimus ointment with maintained treatment efficacy for refractory facial erythema in atopic dermatitis (AD),
however these were only case-controlled studies and the number of cases was not sufficiently large. Thus, the
efficacy of a combination therapy of tacrolimus ointment and suplatast tosilate for treating AD including refrac-
tory facial erythema was investigated using a method of meta-analysis on the basis of published papers col-
lected by database search.
Methods: We searched the literature on the efficacy of a combination of topical tacrolimus and suplatast tosi-
late for refractory facial erythema in patients with adult atopic dermatitis, and related data were collected for
meta-analysis.
Results: Our meta-analysis study showed that suplatasttacrolimus combination therapy revealed better im-
provement in skin symptom scores and significantly decreased the dose of tacrolimus compared with topical
tacrolimus monotherapy. In addition, a significantly greater number of patients could stop using tacrolimus oint-
ment by using the combination with suplatast tosilate than by tacrolimus monotherapy for refractory facial
erythema.
Conclusions: The combination therapy with suplatast tosilate decreased the effective dosage of tacrolimus
ointment supporting use of the combination therapy for refractory facial erythema.
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INTRODUCTION
EFFICACY AND PROBLEMS ASSOCIATED WITH
TOPICAL TACROLIMUS FOR REFRACTORY FA-
CIAL ERYTHEMA
Facial erythema in adult AD, which is called refrac-
tory facial erythema or an atopic red face, is a heavy
psychological burden for a number of patients be-
cause it is chronic and resistant to regular treatment.
A number of causes, such as involvement of mites,
house dusts, and fungi such as Candida and
Malassezia,1 long-term topical application of steroids,2
and concomitant contact dermatitis due to the use of
a variety of topical medicines and cosmetics,3 have
been proposed, however, none of these can explain
the pathogenesis alone.
Traditionally, AD has been treated by the regular
use of topical corticosteroids, which is not a perfect
treatment because sufficient results cannot be pro-
vided in a number of cases due to adverse events
such as steroid-induced skin atrophy. However, since
tacrolimus ointment (ProtopicⓇ) was launched in
1999, it has brought major changes in the treatment
of AD. Tacrolimus ointment exhibits anti-
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Table 1 Patient Background. The results were expressed as means ± SD.
StatisticsTacrolimusTacrolimus and Suplatast
CategoryInventory (p-value)AloneTosilate Combination
4158Number of patients
 0.833 (χ2-test)2737MaleGender
1421Female
0.372 (t-test)27.2 ± 10.027.2 ± 9.2 Age
0.402 (t-test)6.9 ± 1.87.2 ± 1.7Erythema/edema/acuteEczema scores
papulebefore treatment
0.097 (t-test)4.0 ± 2.14.7 ± 2.1Chronic papule/nodule/
lichenification
0.677 (t-test)2.3 ± 1.92.1 ± 2.3Humectation/erosion/crust
0.196 (t-test)13.1 ± 2.4 13.9 ± 3.4 Total
0.707 (t-test)4.0 ± 2.54.2 ± 2.8g/weekDoses of the first
tacrolimus ointment
Fig. 1 Study Profile
Failure to consultation (n ＝ 6) 
Failure to scoring (n ＝ 2)         
Failure to measure tac (n ＝ 1) 
Failure to consultation (n ＝ 4) Failure to consultation (n ＝ 1)
Failure to measure tac (n ＝ 1)  
Failure to consultation (n ＝ 1) 
Failure to scoring (n ＝ 2)         
Failure to measure tac (n ＝ 2) 
Tacrolimus (tac) only
(n ＝ 41)
6 week
Eczema score (n ＝ 33) 
Amount of tac (n ＝ 34) 
6 week
Eczema score (n ＝ 55) 
Amount of tac (n ＝ 55)
10 week
Eczema score (n ＝ 37) 
Amount of tac (n ＝ 37) 
10 week
Eczema score (n ＝ 57) 
Amount of tac (n ＝ 56) 
Tac and Suplatast
tosilate (n ＝ 58)
Enrolled patients
(n ＝ 99)
inflammatory properties as effective as strong-class
topical corticosteroids, and no local adverse events,
such as skin atrophy often observed after the long-
term use of corticosteroids, have been reported.
Therefore, it has been employed mainly for facial and
neck eczema in adult AD patients, and excellent im-
provements have been reported.4
In cases with refractory facial erythema, acute ex-
acerbation associated with edematous erythema is
often observed without exudation, papules, or small
vesicles. Histologically, accumulation and infiltration
of mast cells and eosinophils are often observed in
the epidermis. It has been suggested that these
symptoms may be caused by eosinophilic inflamma-
tion in the dermis due to a late phase allergic reac-
tion.5 Therefore, the regulation of mast cells, Th2
Suplatasttacrolimus Therapy for AD
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Fig. 2 Reduction in the Amount of Tacrolimus Ointment by Suplatast Tosilate Combination. Data were pooled ac-
cording to the random efect model after the test of heterogeneity. Meta-analysis was performed and the results were 
expressed as means ± SD with the 95% confidence interval and the forest plot was also shown. Diferences in the 
mean value were expressed as weighted mean diference (WMD). Suplatast tosilate was administered 400 mg/day 
(b.i.d) in the study by Matsumura15 and Koga,16 and 300 mg/day (t.i.d) in the study by Takenaka.17
2―6 week
Study n n
Reduction in the amount of tacrolimus (g)
Tacrolimus and
Suplatast tosilate
Tacrolimus
only
WMD
95% CI
WMD
95% CI
Matsumura15
Koga16
Takenaka17
Total
15
25
15
3.07 ± 2.02
1.63 ± 2.53
2.03 ± 1.81
1.64 ± 1.75
0.56 ± 1.08
0.50 ± 1.53
55
11
16
8
35
1.43
1.07
1.53
1.30
(－0.02―2.88)
(－0.05―2.19)
(　0.13―2.93)
(　0.55―2.05)
－4 －2 0 2 4
Favours
tacrolimus
only
Favours
tacrolimus and
suplatast tosilate
2―10 week (cases which lack the 10th week values are excepted)
Study n n
Reduction in the amount of tacrolimus (g)
Tacrolimus and
Suplatast tosilate
Tacrolimus
only
WMD
95% CI
WMD
95% CI
Matsumura15
Koga16
Takenaka17
Total
15
26
15
3.17 ± 201
0.88 ± 3.08
4.41 ± 3.83
2.32 ± 1.89
－0.18 ± 1.06
0.50 ± 1.32
56
11
17
8
36
0.85
1.06
3.91
1.75
(－0.66―2.36)
(－0.23―2.35)
(　1.77―6.05)
(　0.13―3.36)
－10 －5 0 5 10
Favours
tacrolimus
only
Favours
tacrolimus and
suplatast tosilate
type cytokines, and proinflammatory factors from
eosinophils that mediate the allergic inflammatory re-
action is important. Tacrolimus ointment is often ef-
fective for such cases by inhibiting the functions of
activated T cell nuclear transcription factors responsi-
ble for transcription of a variety of cytokines.6 On the
other hand, tacrolimus ointment causes skin irritation
and burning sensation at the beginning of treatment,
and infectious skin diseases such as folliculitis, Ka-
posi’s varicelliform eruption, and herpes simplex vi-
rus infection have been reported as clinical prob-
lems.7
EFFICACY AND PROBLEMS ASSOCIATED WITH
SUPLATAST TOSILATE FOR REFRACTORY FA-
CIAL ERYTHEMA
Suplatast tosilate (IPDⓇ) categorized as a Th2 type
cytokine inhibitor suppresses the production of IL-4
and IL-5 in Th2 type cells, and preclinical experi-
ments demonstrated inhibition of eosinophil infiltra-
tion and release of chemical mediators.8 In addition,
serum IL-5 levels,9 peripheral eosinophil counts, and
eosinophil cationic protein (ECP) were reduced by
the administration of suplatast tosilate in clinical stud-
ies.10 Furthermore, a recent prospective study re-
vealed its efficacy for asthma.11 Before tacrolimus
ointment became commercially available, the efficacy
of suplatast tosilate for refractory facial erythema was
demonstrated, however it takes a relatively long time
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Fig. 3 Day-to-day Changes in the Amount of Tacrolimus 
Ointment. Data were pooled according to the random efect 
model after the test of heterogeneity. Diferences in the 
amount of tacrolimus ointment at weeks 6 and 10 were com-
pared between the two groups by Student
, 
s t-test. ＊ :signifi-
cantly diferent from baseline. ##: significantly diferent 
between two groups. The results were expressed as means 
± SE.
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before the emergence of effects and improvement in
skin symptoms and is not as remarkable as topical
tacrolimus.12
A COMBINATION THERAPY OF TOPICAL
TACROLIMUS AND SUPLATAST TOSILATE
It has been reported that a combination with suplatast
tosilate after introduction of remission by tacrolimus
ointment can reduce the dose of tacrolimus ointment
with maintained treatment efficacy for refractory fa-
cial erythema in AD. However, the study was non-
randomized and non-comparative, and the number of
cases was not sufficiently large. Thus, the efficacy of
a combination therapy of tacrolimus ointment and
suplatast tosilate for treating AD including refractory
facial erythema was investigated on the basis of pub-
lished papers collected by a database search.
METHODS
SEARCH STRATEGY
We systematically searched for published works de-
scribing a combination of tacrolimus ointment and
suplatast tosilate for AD on MEDLINE and Japana
Centra Revuo Medicina (Igaku Chuo ZasshiJapa-
nese Central Medical Journal) databases. Research
designs of papers selected for the present study were
randomized comparative trials, comparative clinical
trials, and comparative trials. “Tacrolimus, Protopic,
or FK506”, “Suplatast tosilate or IPD”, “AD”, and “fa-
cial erythema” were used as search terms and all
published reports were extracted.
PARAMETERS FOR EVALUATION
Parameters for evaluation were doses of tacrolimus
ointment, eczema scores, and adverse events.
Amount of tacrolimus ointment used in a week were
measured every week. Degree of “erythema・
edema・acute papule”, “chronic papule・nodule・li-
chenification”, and “humectation・erosion・crust”
were graded from 0 to 3, and the total score was
evaluated from 0 to 27 as the eczema score.
DATA ANALYSIS
Background data were summarized as means ± SD in
each group, and differences between the groups were
analyzed by Student’s t -test and the χ2-test. Average
differences in weekly doses of tacrolimus used at
week 2 and week 8―10 after the beginning of treat-
ment were calculated in the combination group with
suplatast tosilate and the tacrolimus ointment alone
group, which were employed as a marker to evaluate
the effect. Meta-analysis was performed with the
RevMan Analyses (version 1.0.3 for Windows) soft-
ware in the Review Manager (RevMan) (version 4.2
for Windows, The Nordic Cochrane Centre, Copen-
hagen, 2003) provided by the Cochrane Collabora-
tion.13
Differences in the reduced average dose of
tacrolimus ointment and the average improvement in
the eczema score were pooled according to the ran-
dom effect model after the test of heterogeneity.14
Since the three studies employed the same eczema
score, differences in the mean value were expressed
as the weighted mean difference (WMD).
The results were expressed as means ± SD with
the 95% confidence interval and the forest plot was
also shown. After all data were collected, differences
in the dose of tacrolimus ointment at weeks 6 and 10
were compared between the two groups by Student’s
t -test and presented in a graph. Termination rates of
tacrolimus use in trials were compared by Mantel-
Haenszel test. Adverse events were analyzed by χ2-
test separately in each category. A p value less than
0.05 was considered statistically significant.
RESULTS
STUDY SELECTION
Three case-controlled clinical trials published in Ja-
pan were verified to be appropriate.15-17 Data were
provided by the researchers that published the trials,
which were evaluated as appropriate. Data of individ-
ual trials were analyzed and evaluated as follows.
PATIENT BACKGROUND
The case numbers of the tacrolimus ointment alone
group and the suplatast tosilate combination group
were 11 and 15 in the first,15 20 and 28 in the sec-
ond,16 and 10 and 15 in the third study, respectively,
and in total these two groups had 41 and 58 regis-
tered cases, respectively. Study designs of all studies
Suplatasttacrolimus Therapy for AD
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Fig. 4 Improvement in the Eczema Score by the Combination of Suplatast Tosilate and Tacrolimus Ointment. Data 
were pooled according to the random efect model after the test of heterogeneity. Meta-analysis was performed and 
the results were expressed as means ± SD with the 95% confidence interval and the forest plot was also shown. Dif-
ferences in the mean value were expressed as weighted mean diference (WMD). Suplatast tosilate was administered 
400 mg/day (b.i.d) in the study by Matsumura15 and Koga,16 and 300 mg/day (t.i.d) in the study by Takenaka.17
0―6 week
Study n n
Reduction of the eczema score
Tacrolimus and
Suplatast tosilate
Tacrolimus
only
WMD
95% CI
WMD
95% CI
Matsumura15
Koga16
Takenaka17
Total
15
25
15
10.90 ± 4.40
9.40 ± 4.46
9.50 ± 2.26
9.54 ± 2.50
6.80 ± 4.30
8.80 ± 2.60
55
11
14
8
33
1.36
2.60
0.70
1.40
(－1.31―4.03)
(－0.29―5.49)
(－1.53―2.93)
(－0.08―2.87)
p ＝ 0.06
p ＝ 0.09
－10 －5 0 5 10
Favours
tacrolimus
only
Favours
tacrolimus and
suplatast tosilate
0―10 week (cases which lack the 10th week values are excepted)
Study n n
Reduction of the eczema score
Tacrolimus and
Suplatast tosilate
Tacrolimus
only
WMD
95% CI
WMD
95% CI
Matsumura15
Koga16
Takenaka17
Total
15
27
15
11.10 ± 4.80
10.50 ± 2.80
10.40 ± 1.50
9.50 ± 2.40
9.90 ± 2.90
9.60 ± 1.50
57
11
18
8
37
1.60
0.60
0.80
0.83
(－1.21―4.41)
(－1.11―2.31)
(－0.49―2.09)
(－0.13―1.80)
－10 －5 0 5 10
Favours
tacrolimus
only
Favours
tacrolimus and
suplatast tosilate
are shown in Figure 1. The background in all pa-
tients, including gender, age, eczema scores before
treatment, and doses of the first tacrolimus ointment
were compared between the two groups, but there
was no statistically significant bias (Table 1).
EVALUATION OF EFFICACY
Reduction in the Dose of Tacrolimus Ointment
In the three studies comparing the dose of tacrolimus
ointment in the tacrolimus ointment alone group and
the suplatast tosilate combination group between
week 2 and 6 and between week 2 and 10, one study
showed a significant reduction but two studies re-
vealed no statistical difference. However, when the
results of the three studies were meta-analyzed, the
doses of tacrolimus ointment were significantly re-
duced at week 6 and 10 both compared with week 2
(Fig. 2). The suplatast tosilate combination group
showed a significantly reduced amount of tacrolimus
ointment used at week 10 compared with the
tacrolimus ointment alone group (Fig. 3).
Improvement in the Eczema Score
In the three studies that compared the tacrolimus
ointment alone group and the suplatast tosilate com-
bination group, there was no statistical difference in
the eczema score at week 0 and 6, or week 0 and 10.
However, when the results of the three studies were
meta-analyzed, p values for the comparison between
week 0 and 6 and between week 0 and 10 were 0.06
and 0.09, respectively, which showed a tendency for
improvement (Fig. 4).
Use of tacrolimus ointment was stopped by week
10 in 14 of 58 cases (24.1%) in the suplatast tosilate
group and in 3 of 41 cases (7.3%) in the monotherapy
group, and the combination with suplatast tosilate
Miyachi Y et al.
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Table 2 Termination Rates of Tacrolimus Ointment Use.
 Statistics
(Mantel-Haenszel test)
Tacrolimus Alone
(n＝41)
Combination
(n＝58)Group
P＝0.00233 (7.3%) 14 (24.1%) Number of patients who 
discontinued the use of 
tacrolimus 
Table 3 Adverse Efects
p-valueTacrolimus AloneCombination
Inventory (χ2-test)(n＝41)(n＝58)
0.983710Iritation
0.3873 2Acne or acne-like eruption
0.3980 1Secondary infection
0.3980 1Drowsiness
0.2321 0Burning sensation
0.3980 1Herpes simplex
could stop the use of tacrolimus ointment at a signifi-
cantly higher rate (p = 0.002) (Table. 2).
There was no statistical difference in the occur-
rence of adverse events between the two groups (Ta-
ble 3).
DISCUSSION
The underlying mechanisms for the efficacy of topical
tacrolimus for facial and neck eczema of adult AD
have been reported and include the following: inhibi-
tion of (1) cytokine production from Th1 and Th2
cells; (2) antigen presentation by Langerhans cells;
(3) histamine release from mast cells and basophils;
(4) release of cytotoxic substances from eosinophils;
and (5) chemokine production for eosinophils by
cytokine-stimulated epidermal cells.7 Among adult
AD cases, the following findings have been made:
topical tacrolimus has been used in cases such as ec-
zema on the face and neck that often causes local ad-
verse effects from the long-term use of topical corti-
costeroids; local adverse effects have already ap-
peared due to topical corticosteroids; and contraindi-
cation for corticosteroids. Indeed, a number of cases
of excellent improvements have been reported.4
On the other hand, approximately 80% of patients
who used tacrolimus ointment for neck and facial ec-
zema complained of skin irritation symptoms such as
burning sensation, pain, and warmth, and some of
them, but not many, were forced to stop the use due
to severe irritation. Nakagawa et al. reported the re-
sults of long-term use of topical tacrolimus, and the
occurrence rate of skin infection was 20.8%, which
comprised of folliculitis at 12.0%, acne or acne-like
eruption at 7.4%, Kaposi’s varicelliform eruption at
4.2%, and herpes simplex virus infection at 3.3%.
These are clinical problems for the application.7
Suplatast tosilate inhibits the production of IL-4 and
IL-5 by Th2 type cells and exerts anti-allergic proper-
ties by suppressing not only the release of chemical
mediators but also IgE antibody production and infil-
tration of eosinophils. It has been used to treat AD,
bronchial asthma, and allergic rhinitis.
The results of the present study revealed that the
combination with suplatast tosilate could reduce the
dose or even remove the need for the use of
tacrolimus ointment. There was no statistical differ-
ence in the improvement of eczema between the
suplatast tosilate combination group and the
tacrolimus ointment alone group. When the results of
the three studies were meta-analyzed, the combina-
tion therapy showed a tendency of improvement with
p values of 0.06 and 0.09 between week 0 and 6 and
between 0 and 10, respectively, although the lower
limits of the confidence interval were below zero and
−0.08 and −0.13, respectively. Further accumulation
of such cases may eventually indicate a significant im-
provement by the combination therapy. Because the
total number of cases of these studies was small and
they were done by case-controlled trials, and there
might be a publication bias, analysis further studies
are required.
These results suggest that the combination with
suplatast tosilate is a useful option for treatment of
adult AD. Although the underlying mechanisms that
could reduce the amount of tacrolimus ointment re-
main to be clarified, a combination of steroid inhala-
tion and suplatast tosilate was reported to reduce the
amount of inhaled steroids for severe bronchial
asthma, similarly to the results in the present study.10
The similarity implicates the involvement of a certain
common mechanism. It is expected that clinical trials
with even-higher levels of evidence will verify the re-
sults.
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